<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12655">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465894</url>
  </required_header>
  <id_info>
    <org_study_id>F061208008</org_study_id>
    <secondary_id>IIR - DRIVE</secondary_id>
    <nct_id>NCT00465894</nct_id>
  </id_info>
  <brief_title>Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms</brief_title>
  <acronym>DRIVE</acronym>
  <official_title>Randomized Controlled Trial of Tolterodine in Combination With or Without Low-Dose Intra-Vaginal Estradiol Cream for the Treatment of Overactive Bladder in Post-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if long acting tolterodine confers more benefit
      than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12
      weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen
      confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms.
      Secondary outcomes were to assess if the addition of the other therapy to the treatment
      regimen conferred benefit at 24 weeks and 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower urinary tract bladder storage symptoms include urinary frequency, urinary urgency,
      nocturia and urge incontinence. Overactive Bladder (OAB)Syndrome is a condition in which
      urgency is the predominant symptom with or without urge incontinence and is usually
      accompanied by frequency and nocturia. The mainstay of treatment of women with OAB syndrome
      is treatment with anticholinergic medication as well as behavioral therapy. This method of
      treatment has demonstrated a 60% response rate as reported in the Cochrane Database of
      Systemic Reviews.

      In addition to anticholinergic therapy, vaginal atrophy is often corrected as part of a
      pharmacologic treatment plan. Vaginal atrophy is a condition this is vastly prevalent in
      post-menopausal women. It is thought to affect up to 48% of post-menopausal women. Many
      women with this condition experience vaginal dryness, irritation, painful intercourse, as
      well as urinary symptoms including dysuria, urgency, frequency, nocturia, incontinence and
      recurrent urinary tract infections.

      Comparison: Tolterodine LA compared to low dose intra-vaginal estrogen cream for the
      treatment of OAB symptoms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subjective Patient Improvement in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at 12 Weeks Post Intervention Initiation</measure>
    <time_frame>After 12 Weeks of Intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>OAB-q scoring ranges from a lowest score of 8 to the highest score of 48. The higher score reflects greater severity of symptoms. The derived score is (actual score - lowest raw score) divided by possible raw score range (40) times 100. Hence, the lowest score is 0 and the highest score is 100, with 100 being indicative or greater symptom severity. The mean and the standard deviation is reported for both arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Patient Improvement in Irritative Urinary Symptoms at 12 Weeks Post Intervention Initiation</measure>
    <time_frame>After 12 Weeks of Intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health Related Quality of Life (HRQL) portion of the OAB-q
Patient Global Impression of Improvement (PGI-I)
Patient Satisfaction Questionnaire (PSQ)
3-Day Voiding Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Patient Improvement in Irritative Urinary Symptoms at 24 and 52 Weeks Post Intervention Initiation</measure>
    <time_frame>After 24 and 52 Weeks of Intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>OAB-q Symptom Bother Score
Health Related Quality of Life (HRQL) portion of the OAB-q
Patient Global Impression of Improvement (PGI-I)
Patient Satisfaction Questionnaire (PSQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Extended Release Tolterodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra Vaginal Estradiol Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine LA</intervention_name>
    <description>Tolterodine LA 4 mg once daily for 52 weeks</description>
    <arm_group_label>Extended Release Tolterodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrace Vaginal Cream</intervention_name>
    <description>17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks</description>
    <arm_group_label>Intra Vaginal Estradiol Cream</arm_group_label>
    <other_name>Premarin vaginal cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Irritative voiding symptoms to include sensory urgency, frequency, urge incontinence,
             nocturia

          -  Postmenopausal women with a prior oophorectomy or 1 year from last menstrual period

          -  Women age 40-90

          -  Women with hysterectomy with preserved ovaries must be age 55 or greater or have a
             documented FSH&gt;40 to ensure post-menopausal status

          -  Community dwelling

          -  Ambulatory

          -  Ability to participate in a 12 month study

        Exclusion Criteria:

          -  Post-void residual volume&gt;150ml

          -  Glaucoma without ophthalmologist clearance

          -  Hormone replacement therapy in the past 6 months

          -  Current anticholinergic treatment

          -  Breast cancer

          -  Impaired mental status

          -  Undiagnosed vaginal bleeding in the past 12 months

          -  Endometrial thickness on pelvic ultrasound &gt;5mm

          -  History of thromboembolic event

          -  Gynecologic cancer

          -  Untreated urinary tract infection (would be eligible after treatment)

          -  Stage III pelvic organ prolapse or greater

          -  Recent diuretic medication changes (one month from change)

          -  Neurologic condition affecting bladder function (Multiple Sclerosis, Parkinsons,
             spinal cord injury, spina bifida)

          -  Congestive heart failure

          -  Prior pelvic irradiation

          -  Interstitial cystitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Gerten, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Nicollette, St. Louis, Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly E. Richter, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>August 15, 2015</lastchanged_date>
  <firstreceived_date>April 23, 2007</firstreceived_date>
  <firstreceived_results_date>June 1, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>urge leakage</keyword>
  <keyword>nightime urination</keyword>
  <keyword>incontinence</keyword>
  <keyword>urinary frequency</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Tolterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Extended Release Tolterodine</title>
          <description>4 mg Tolterodine po daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Intra Vaginal Estradiol Cream</title>
          <description>0.5 grams of Intra vaginal estradiol cream nightly for 6 weeks, then twice weekly for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Extended Release Tolterodine</title>
          <description>4 mg Tolterodine po daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Intra Vaginal Estradiol Cream</title>
          <description>0.5 grams of Intra vaginal estradiol cream nightly for 6 weeks, then twice weekly for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63" spread="6"/>
                <measurement group_id="B2" value="60" spread="2"/>
                <measurement group_id="B3" value="61.5" spread="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Patient Improvement in Irritative Urinary Symptoms at 12 Weeks Post Intervention Initiation</title>
        <description>Health Related Quality of Life (HRQL) portion of the OAB-q
Patient Global Impression of Improvement (PGI-I)
Patient Satisfaction Questionnaire (PSQ)
3-Day Voiding Diary</description>
        <time_frame>After 12 Weeks of Intervention</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Patient Improvement in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at 12 Weeks Post Intervention Initiation</title>
        <description>OAB-q scoring ranges from a lowest score of 8 to the highest score of 48. The higher score reflects greater severity of symptoms. The derived score is (actual score - lowest raw score) divided by possible raw score range (40) times 100. Hence, the lowest score is 0 and the highest score is 100, with 100 being indicative or greater symptom severity. The mean and the standard deviation is reported for both arms.</description>
        <time_frame>After 12 Weeks of Intervention</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Extended Release Tolterodine</title>
            <description>4 mg Tolterodine po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Intra Vaginal Estradiol Cream</title>
            <description>0.5 grams of Intra vaginal estradiol cream nightly for 6 weeks, then twice weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of of Partipants at 12 Weeks analyzed</title>
            <units>of Partipants at 12 Weeks</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subjective Patient Improvement in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at 12 Weeks Post Intervention Initiation</title>
            <description>OAB-q scoring ranges from a lowest score of 8 to the highest score of 48. The higher score reflects greater severity of symptoms. The derived score is (actual score - lowest raw score) divided by possible raw score range (40) times 100. Hence, the lowest score is 0 and the highest score is 100, with 100 being indicative or greater symptom severity. The mean and the standard deviation is reported for both arms.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.4" spread="15.3"/>
                  <measurement group_id="O2" value="61.6" spread="20.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.7" spread="23.4"/>
                  <measurement group_id="O2" value="45.4" spread="21.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Patient Improvement in Irritative Urinary Symptoms at 24 and 52 Weeks Post Intervention Initiation</title>
        <description>OAB-q Symptom Bother Score
Health Related Quality of Life (HRQL) portion of the OAB-q
Patient Global Impression of Improvement (PGI-I)
Patient Satisfaction Questionnaire (PSQ)</description>
        <time_frame>After 24 and 52 Weeks of Intervention</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Extended Release Tolterodine</title>
          <description>4 mg Tolterodine po daily for 12-weeks</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Intra Vaginal Estradiol Cream</title>
          <description>0.5 grams of Intra vaginal estradiol cream nightly for 6 weeks, then twice weekly for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Holly E. Richter</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-1704</phone>
      <email>hrichter@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
